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~ Abstract 
Early chronic liver allograft rejection (CR) is characterized by distinctive 
cytological changes in biliary epithelial cells (BECs) that resemble cellular 
senescence, in vitro, and precede bile duct loss. If patients suffering from 
early CR are treated aggressively, the clinical and histopathological 
manifestations of CR can be completely reversed and bile duct loss can be 
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prevented. We first tested whether the senescence-related p21 W AFlICip 1 protein is increased in BECs 
during early CR, and whether treatment reversed the expression. The percentage of p21 + BECs and 
the number ofp21 + BECs per portal tract is significantly increased in early CR (26 ± 17% and 3.6 ± 
3.1) compared to BECs in normal liver allograft biopsies or those with nonspecific changes (1 ± 1 % 
and 0.1 ± 0.3; P < 0.0001 andP < 0.02), chronic hepatitis C (2 ± 3% and 0.7 ± 1; P < 0.0001 and P < 
0.04) or obstructive cholangiopathy (7 ± 7% and 0.7 ± 0.6; P < 0.006 and P = 0.04). Successful 
treatment of early CR is associated with a decrease in the percentage of p21 + BECs and the number of 
p21 + BECs per portal tract. In vitro, nuclear p21 WAFlICipl expression is increased in large and 
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multinucleated BECs, and is induced by transfonning growth factor (TGF)-B. TGF-Bl also increases 
expression ofTGF-B receptor II, causes phosphorylation ofSMAD-2 and nuclear translocation of 
p21 WAF l/Cip 1, which inhibits BEC growth. Because conversion from cyclosporine to tacrolimus is an 
effective treatment for early CR, we next tested whether these two immunosuppressive drugs directly 
influenced BEC growth in vitro. The results show that cyclosporine, but not tacrolimus, stimulates 
BEC TGF-Bl production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear 
p21 WAFlICipl. In conclusion, expression ofthe senescence-related p21 WAFlICipl protein is increased 
in BECs during early CR and decreases with successful recovery. Replicative senescence accounts for 
the characteristic BEC cytological alterations used for the diagnosis of early CR and lack of a 
proliferative response to injury. The ability of cyclosporine to inhibit the growth of damaged BECs 
likely accounts for the relative duct sparing properties of tacrolimus. 
~ Introduction 
Early chronic liver allograft rejection (CR) is characterized by cytological 
alterations in biliary epithelial cells (BECs), such as cellular and nuclear 
enlargement, multinucleation, aggregation of dense bundles of cytoplasmic 
filaments and cytoplasmic eosinophilia, which results in uneven nuclear 
spacing and thickening of the basement membraneKl-~ These are well-
"'IQll 
"DAb~1r:u:t 
• Introduction 
• MaKl~d~lfsitmg Metho(ls 
• Results 
..... ais~yssi~1! 
• References 
described changes of cellular senescence in vitro and in vivo,2-12 including primary cultures ofhurnan 
BECs, which enlarge, cease dividing, become multinucleated and squamoid-appearing before finally 
detaching from the plates)l Senescent cells also express p21 WAF lICip 1 2,Jj,15 and forced 
overexpression ofp21 WAFI/Cipl causes cellular senescence and decreased replicative capacity.H 
Despite the BEC damage in early CR, there is no compensatory proliferation, which is unusual 
because BECs usually divide in response to injury. 1S-1~ 
If patients with early CR are treated aggressively, the clinical, biochemical, and histopathological 
manifestations of CR can be reversedlI~IEFI1O-O1 and bile duct loss, which is a late feature of CR, 1 can 
be prevented. Rare instances of spontaneous reversal of early CR have also been reported.1,J 
Interestingly, tacrolimus decreases the overall incidence ofCR and liver allografts that do fail because 
of CR under tacrolimus show less bile duct loss than cyclosporine-treated recipients. 5-] In vitro 
cyclosporine, but not tacrolimus, can induce epithelial production of transfonning growth factor 
(TGF)-B,22-2-1: which inhibits epithelial cell growth via induction of p21 WAFIICipl. 
In these studies, we tested the hypothesis that the characteristic phenotypic changes seen during early 
CR were because ofBEC replicative senescence, and therefore, should be associated with increased 
expression of p21 WAF l/Cip 1. Because successful treatment of early CR reverses the BEC alterations, a 
decrease in p21 WAFI/Cipl should be observed in association with recovery. Furthermore, given the 
relative duct sparing qualities of tacrolimus in comparison to cyclosporine,6 we hypothesized that the 
primary immunosuppressant drug might contribute to this process by influencing endogenous BEC 
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TGF-B production and BEC growth. 
~ Materials and Methods 
Patient Selection and Immunohistochemistry for p21WAFIICipi 
Patients were selected for study from two different groups. The first group 
consisted of patients who were converted from cyclosporine to tacrolimus 
during the original rescue trial conducted from 1989 until 1991.2 J Patients 
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from this group were chosen to determine the effect of the primary immunosuppressant on BEC 
p21 WAFIICipl expression in various allograft syndromes: obstructive cholangiopathy (n = 3), chronic 
viral hepatitis (n = 3), early chronic rejection (n = 5), or nonspecific changes (n = 8). Individual 
patients were selected on the basis of the availability ofa liver allograft biopsy obtained within 8 days 
before, and after conversion to tacrolimus, along with enough tissue remaining in each of the paraffin 
blocks to carry out the immunohistochemical stains. Biopsies were obtained at a median of 889 days 
after transplantation and all but one was obtained more than 3 months after transplantation. The 
second group consisted of randomly selected tacrolimus-treated patients who were experiencing 
obstructive cholangiopathy (n = 4); chronic hepatitis, viral type C (n = 5); or early chronic rejection (n 
= 3). These biopsies were obtained at a median of938 days after transplantation. 
An indirect immunolabeling procedure after microwave antigen retrieval in 10 mmollL citrate buffer 
(pH 6.0), was used to localize p21 WAFlICipl protein expression in the human liver allograft biopsies 
(Waf-I, 1 :50 dilution, Cat No. OP64; Oncogene Research, Cambridge, MA) and in primary cultures 
of mouse BECs (mBECs) (SXI18; DAKO, Carpinteria, CA). Briefly, after antigen retrieval, samples 
were blocked with Blue Block (Shandon, Pittsburgh, P A) for 15 minutes, and then incubated with the 
primary antibody for 1 hour at room temperature. After washing with phosphate-buffered saline (PBS) 
plus 0.05% Tween 20, slides were incubated at room temperature for 30 minutes with biotinylated 
horse anti-mouse secondary antibody (1 :200 dilution, BA 2000; Vector Laboratories, Burlingame, 
CA). The samples were then developed with Vectastain-Elite ABC (Vector Laboratories), stained with 
liquid Dab+ (DAKO) and counterstained with hematoxylin. An immunoglobulin class-matched 
nonimmune antibody was substituted for the primary antibody in the negative controls. For the 
mBECs, 10,000 BECs were seeded on collagen-coated glass cell chamber slides (Nunc, Rochester, 
NY) and cultured for 3 days in complete serum-free medium (described below), followed by formalin 
fixation. Staining for p21 WAF lICip 1 protein in the mBECs was enhanced by tyramide amplification 
(New England Nuclear-Life Sciences, Boston, MA). 
For the human liver allograft biopsies, the total number ofBECs showing strong nuclear 
p21 WAFIICipl positivity, the total number ofBECs, and the total number of complete portal tracts 
were counted for each biopsy, without knowledge of whether the biopsy was obtained before or after 
conversion to tacrolimus, or the diagnosis. However, in most cases, the histopathological diagnosis 
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was obvious, and true blinding of the samples was not possible. The expression ofp21 WAFIICipl in 
BECs was expressed as both the percentage ofBEC that were p21 WAFI/Cipl_positive and the absolute 
number ofp21 WAFliCipl_positive BECs per portal tract. 
Mice and Isolation of mBECs 
Eight- to twelve-week-old male mice of a mixed strain consisting of75% (CJ57BL/6) and 25% 
(SV129) were used in this study. The mice were housed in a pathogen-free environment at the 
University of Pittsburgh. Primary cultures ofmBECs were prepared as previously reportedKO~ For all 
experiments (except where noted), BECs were cultured in complete serum-free medium (C-SFM), 
consisting of Dulbecco's modified Eagle mediurnlF12 medium (Sigma, St. Louis, MO) supplemented 
with 5.4 gIL D-glucose (Life Technologies, Inc., Rockville, MD), 50 ).lg/ml gentamicin (Life 
Technologies, Inc.), antibiotic-antimycotic (100 U/ml penicillin G sodium, 100 ).lg/ml streptomycin 
sulfate, 250 ng/ml amphotericin B; Life Technologies, Inc.), 10 mmollL HEPES (Life Technologies, 
Inc.), 2.5 mg/ml bovine serum albumin (Sigma), insulin-transferrin-selenium X (10 mgIL insulin, 5.5 
mgIL transferrin, 6.7 nglL sodium selenite; Life Technologies, Inc.), 0.1 mmollL minimal essential 
media nonessential amino acid solution (Life Technologies, Inc.), 2 mmollL L-glutamine (Life 
Technologies, Inc.), 32 ng/ml thyroxin (Sigma), 10 ng/ml prostaglandin El (Sigma), 40 ng/ml 
hydrocortisone (Sigma), 10 ).lmollL forskolin (Sigma), and 50 ).lg/ml trypsin inhibitor (Sigma). 
Proliferation Assay for mBECs 
For these experiments, mBECs were seeded at a density of 1 x 10:+ cells per well on collagen-coated 
96-well flat-bottom plates (BD Falcon, Franklin Lakes, NJ) in C-SFM supplemented with 50 ).lg/ml of 
bovine pituitary extract (BPE) (Life Technologies, Inc.) and 10 ng/ml epidermal growth factor (EGF) 
(Life Technologies, Inc.). The cells were grown until 50% confluent when the media was removed. 
The cells were then washed two times at 37°C in Hanks' balanced salt solution (HBSS) (Life 
Technologies, Inc.), and kept for 24 hours in simple serum-free medium (S-SFM) consisting of 
Dulbecco's modified Eagle's mediurnlF12 medium (Sigma) supplemented with 5.4gIL D-glucose (Life 
Technologies, Inc.), 50 ).lg/ml gentamicin (Life Technologies, Inc.), antibiotic-antimycotic (100 
units/ml penicillin G sodium, 100 ).lg/ml streptomycin sulfate, 250 ng/ml amphotericin B; Life 
Technologies, Inc.), 10 mmollL HEPES (Life Technologies, Inc.), and 2.5 mglml bovine serum 
albumin (Sigma). The BECs were then switched to C-SFM alone or C-SFM supplemented with either 
cyc1osporine A or tacrolimus for 48 hours (kindly donated from Dr. A. Zeevi and Dr. R. 
Venkataranam, University of Pittsburgh, Pittsburgh, PA). Twenty-four hours before harvesting, cells 
were treated with 1.0 ).lCi of eH]-thymidine to each well. 
Protein and mRNA Analysis 
For both mRNA and protein studies, mBECs were seeded onto collagen-coated plates or flasks and 
grown to 70% confluence in C-SFM + BPE + EGF, washed twice at 37°C in HBSS, and then treated 
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with cyc1osporine, tacrolimus, or control media (C-SFM) for 48 hours. The media was removed and 
saved for analysis ofTGF-Bl protein concentration by TGF-Bl Emax ImmunoAssay System 
(Promega, Madison, WI). 
Total RNA was isolated for the cells using the TRlzol reagent (Life Technologies, Inc.) and TGF-Bl 
mRNA was assayed by RiboQuant ribonuclease protection assay (BD Pharmingen, San Diego, CA). 
Five Jlg of total RNA was assayed according to the manufacturer's protocol. Gels were dried and 
analyzed by phosphoimaging (Molecular Dynamics, Sunnyvale, CA). The signals were quantified using 
the NIH Image analysis software. 
Total celllysates were prepared by treating the cells with RlPA buffer at 4°C for 1 hour. Lysates were 
cleared by centrifugation at 14,000 x g for 30 minutes and the supernatant was collected and stored at 
-80°C. Nuclear and cytosolic protein fractions were extracted by lysing the cells on ice with a buffer 
containing 10 mmollL HEPES, 1.5 mmollL MgCI2, 10 mmollL hC~ 0.1% TritonX-100, 10 Jlg/ml 
leupeptin, 4 Jlg/ml aprotinin, 1 mmollL k~ VO 4' 1 mmoVL phenylmethyl sulfonyl fluoride, and 1 
mmollL dithiothreitol for 10 minutes on ice. Lysates were centrifuged at 7,000 x g for 5 minutes at 4° 
C and the supernatant was saved as cytosolic protein at -80°C. The residual pellet was then incubated 
in a buffer containing 20 mmollL HEPES, 1.5 mmollL MgCIz, 0.1 % Triton X-I 00, 0.2 mmollL 
ethylenediaminetetraacetic acid, 420 mmollL kaC~ 20% glycerol, 10 Jlg/mlleupeptin, 4 Jlg/ml 
aprotinin, 1 mmollL k~ VO 4' 1 mmollL phenylmethyl sulfonyl fluoride, and 1 mmollL dithiothreitol 
and then centrifuged for 15 minutes at 13,000 x g. The supernatant was saved as nuclear protein at-
80°C. Forty Jlg of total cell lysate was separated by 8% sodiwn dodecyl sulfate-polyacrylamide gel 
electrophoresis gel, transferred to nitrocellulose membrane, and probed with anti-TGF-B receptor II 
(Santa Cruz Biotechnology, Santa Cruz, CA) or phospho-SMAD-2 (Upstate Biotechnology, Lake 
Placid, NY). The nuclear fraction (100 Jlg) was separated by 15% sodiwn dodecyl sulfate-
polyacrylamide gel electrophoresis and used to probe for p21 WAFlICipl (Santa Cruz Biotechnology, 
Santa Cruz, CA). 
Anti-TGF-j3 Blocking 
This experiment was done to determine whether the BECs mito-inhibitory effect ofTGF-B could be 
inhibited by neutralizing anti-TGF-B antibodies. BECs were prepared as above, and simultaneously 
treated with cyclosporine and anti-TGF-B neutralizing monoclonal antibody (R&D Systems) or control 
mouse IgG (Santa Cruz Biotechnology) for 48 hours and assayed for thymidine incorporation, as 
described above. 
Isolation and Culture of Human BECs 
Primary cultures of normal human BECs were prepared using a modification of a method reported by 
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biliary tree from normal livers were used as an explant source. The normal human livers were 
harvested for transplantation, but not used because of steatosis or other contra-indications that did not 
affect BEC viability. Liver tissue was supplied by Dr. S. Strom (University of Pittsburgh) through the 
NIH Liver Tissue Procurement and Distribution System The biliary tree was isolated by digesting the 
entire liver via collagenase perfusion of the portal vein and removing hepatocytes, as previously 
reported.n Mechanical disruption with forceps and gentle shaking at 37°C in a 25% collagenase 
solution was used to remove any residual hepatocytes from the biliary tree, until the white portal 
connective tissue containing the bile ducts was isolated. Tiny fragments of the biliary tree were then 
washed three times in HBSS, resuspended in complete growth factor-supplemented serum-free 
mediunl (CGF-SFM), consisting ofC-SFM + BPE + EGF + 20 ng/ml hepatocyte growth factor 
(Toyoba New York Inc., New York, Ny), minced thoroughly, placed on collagen-coated plates with a 
minimal volume ofC-SFM and allowed to attach for 1 hour at 37°C in a humidified incubator. The 
plate was then carefully covered with C-SFM + BPE + EGF + hepatocyte growth factor to avoid 
disrupting the attached fragments from the plates. The media was replaced after 24 hours and then 
every 4 to 5 days thereafter. BECs were seen growing from the explants within 2 to 3 weeks. After 
substantial growth ofBECs, the cells were treated with cyclosporine or tacrolimus as per individual 
experiments. 
Proliferation Assay for Human BEes 
The biliary tree fragments were maintained in culture for several weeks until the normal human BECs 
began migrating from the explant. The total area of the explant and surrounding BEC colonies were 
then calculated using digital photography and area morphometry (Optimas 6.0 software; Media 
Cybernetics, Silver Springs, MD). An equal number of fragments showing an equivalent outgrowth of 
BECs were treated with either cyclosporine or tacrolimus, or left in CGF-SFM. Media was replaced 
every 2 days. Each explant was photographed every 2 days for a total of 6 days and the area 
determined was compared to that measured on day o. These experiments were repeated twice. 
Additionally, explants cultured as above for 6 days were also labeled with BrdU (10 llmoVL) for 6 or 
12 hours before staining. To determine the percentage of labeled nuclei, 1,500 BECs were counted 
(500 cells, three times), without knowledge of treatment. 
Statistical Analysis 
All data are reported as the mean ± SD. Statistical analysis for the difference in BEC nuclear 
p21 WAF l/Cip 1 protein expression in human liver allograft biopsies between the various causes of liver 
allograft dysfunction used the Wilcoxon rank sum test. Statistical analysis for the difference in vitro 
assays used the Student's (-test. A P value less than 0.05 was considered significant. 
~ Results 
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Expression of p21 WAFJ/CipJ Protein in BECs in Liver Allograft 
Biopsies from Patients with Early Chronic Rejection and Other 
Causes of Late Liver Allograft Dysfunction 
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tract is significantly increased in early CR (26 ± 17% and 3.6 ± 3.1) compared to BECs in normal liver 
allograft biopsies or those with nonspecific changes (1 ± 1 % and 0.1 ± 0.3; P < 0.0001 and P < 0.02), 
chronic hepatitis C (2 ± 3% and 0.7 ± 1; P < 0.0001 and P < 0.04), or obstructive cholangiopathy (7 ± 
7% and 0.7 ± 0.6; P < 0.006 and P = 0.04). Immunohistochemical staining for p21 protein was also 
detected in periportal and perivenular hepatocytes in liver allografts with CR and is the subject of 
further study in our laboratories. 
Cyclosporine-treated recipients suffering from the early stage of CR and rescued after conversion to 
tacrolimus, 1,:U all showed a decrease in the percentage of p21 + BECs and all but one showed a 
decrease in the number of p21 + BECs per portal tract. In the last biopsy with early CR before 
conversion to tacrolimus, 13 to 68% of the BECs were p21 WAFIICipl+ and there was 1.5 to 12 p21+ 
BECs per portal tract (Figure 1, A and CF~ . After conversion to tacrolimus, the percentage of 
p21 WAFIICipl+ BECs decreased to 2 to 27% and the number ofp21+ BECs decreased to 0 to 3 per 
portal tract 11 to 233 days after conversion. Some of these patients were no longer considered to have 
early CR after conversion (Figure 1, B and CF~ . In two cyclosporine-treated recipients with early CR 
who failed to respond to tacrolimus conversion, follow-up biopsies and/or failed allograft showed loss 
of bile ducts in more than 90% ofthe small portal tracts, precluding evaluation of nuclear 
p21 WAF lICip 1. In contrast, neither the percentage nor the number of p21 + BECs per portal tract 
decreased after conversion to tacrolimus in patients without early CR (data not shown). In 0 bstructive 
cholangiopathy, which can also cause ductopenia, the percentage of p21 + BECs was increased (7 ± 
7%) compared to nonspecific changes (1 ± 1 %; P < 0.01) or chronic hepatitis C (2 ± 3%; P < 0.06). 
However, when expressed as the number of p21 + BECs per portal tract the difference between 
obstructive cholangiopathy and nonspecific changes (P = 0.17) or chronic HCV (P = 0.14) was not (or 
only marginally) statistically significant. 
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Figure 1. A: High-power photomicrograph of a 
representative portal tract from a liver allograft recipient with 
early CR stained for p21 WAFlICipl (brown-red nuclei). This 
biopsy was obtained 8 days before conversion to tacrolimus 
immunosuppression, when 36% of the BEC nuclei expressed 
p21 WAFlICipl protein (arrows). Note also the enlarged BEC 
cytoplasm and uneven nuclear spacing, features typical of 
early CR. B: Repeat biopsy ofthe same patient, 36 days after 
conversion to tacrolimus, showed that coincident with clinical 
improvement, the percentage ofp21 WAFI/Cipl+ BECs had 
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as shown in this representative portal tract. C: This graph 
shows the effect of conversion from cyclosporine to 
tacrolimus on BEC p21 WAFIICipl expression in liver allograft 
biopsies with either early CR or nonspecific changes. The 
values at time 0 are the percentages ofBECs that stain 
positive for p21 WAFlICipl in the last biopsy obtained while 
the patient was on cyclosporine. The lines connect 
consecutive biopsies from the same patient. At time 0, note 
the increased percentage of p21 W AFIICip 1 + BECs in 
recipients with early CR compared to those with nonspecific 
changes. Note also, that the percentage ofp21 WAFlICipl+ 
BEC decreases after conversion to tacrolimus in patients with 
early CR. In contrast, there was no change in the percentage 
of p21 WAF I1Cip 1 + BECs in biopsies with nonspecific changes, 
or in chronic HCV (data not shown). 
Senescence of BECs, a Comparison of in Vivo to in Vitro 
We had previously shown that as primary cultures ofhurnan BECs age, the cells enlarge~ cease 
dividing, become multinucleated and squamoid-appearing, and detach finally from the plate;U the 
same is true of mBECs. These cytological alterations are quite similar to those seen in early CR 
(Figure OA~ and are well-described changes of cellular senescence,2-12 as is p21 WAFlICipl 
expression. 14,L'i We therefore determined whether senescent cells in primary cultures ofmBECs 
showed expression of nuclear p21 W AFIICip 1 as did the BECs in early CR. The results are shown in 
Figure OB~K There was preferentialp21 WAFI/Cipl nuclear labeling in the large, multinucleated, 
senescent BECs, whereas the smaller cells were unlabeled (Figure 2B)1!J . 
Figure 2. A: Immunohistochemical stain for p21 WAFlICipl 
(brown nuclei) in a liver allograft biopsy with early CR. Note 
the BEC cytological alterations, including multinucleation 
(arrow), uneven nuclear spacing, and cellular enlargement, 
along with the increased p21 WAFIICipl nuclear labeling. B: 
Immunohistochemical stain for p21 WAF IICip 1 in primary 
cultures of mBEC (brown nuclei). Note the similarity between 
the damaged BEC in the bile duct with early CR (A and C) 
tKKI:;::!iiKKKKKKK:;:~~~!KKKK!~:fi::tff!:sKtKKKKKKK;Dlu and the enlarged senescent mBECs in the primary cultures. 
View larger version (156K): Both cell populations show multinucleation and cytoplasmic 
[in thi~ windoJYl enlargement and occasional cells show nuclear pyknosis. Note 
[in a. new window] also that both the enlarged cells in the primary BEC cultures 
and the BECs in damaged bile duct express nuclear 
p21 WAF IICip 1, but smaller cells do not. C and D: Staining of 
serial sections from a biopsy with early CR for p21 WAFlICipl 
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(C) and Ki-67(Mib-l) (D) shows that the BEC up-regulation 
of p21 W AFlICip 1 is not associated with mitotic activity. 
To exclude the possibility that BEC expression ofp21 WAFI/Cipl was because ofa postmitotic up-
regulation, serial sections of liver allograft biopsies from two patients with increased p21 WAFI/Cipl 
expression were stained for p21 WAFI/Cipl and Ki-67 using the Mib-l antibody (Figure 2, C and a~I 
respectively). Despite the increased p21 WAF lICip 1, there was no Ki-67 labeling. 
Effect of Cyclosporine and Tacrolimus on BEC Proliferation in Vitro 
Conversion from cyclosporine to tacrolimus is the most effective treatment for early CR and successful 
recovery reverses the BEC cytological alterations, and decreases p21 WAFIICipl expression (Figure 
lCF~ . In addition, less ductopenia is observed in liver allografts that fail because ofCR in tacrolimus-
treated patients. () We therefore hypothesized that the primary immunosuppressant drug might directly 
influence BEC viability and growth. Previous studies show that cyclosporine (but not tacrolimus) 
induces production of TGF -B in other epithelial cells,2:Z-fJ: which inhibits their growth, in vitro, via 
induction ofp21 WAFIICipl. 
For these experiments, an equal number ofnonnal human BEC colonies grown from bile duct explants 
in complete growth factor-supplemented SFM media (CGF-SFM) were changed to simple SFM for 24 
hours before the addition of cyclosporine, tacrolimus, or CGF-SFM. Just before the addition of the 
drugs, the size of each colony was determined by digital photography and area morphometry, as 
described in the Materials and Methods. On average, five colonies were included in each treatment 
group. Measurements of colony area were made every 2 days for 6 days. Human BEC colonies kept in 
CGF-SFM supplemented with 1,000 nglml ofcyclosporine showed a significant reduction in area 
compared to the same colonies on day 0 or the area of colonies kept in CGF-SFM or CGF-SFM 
supplemented with tacrolimus (1,000 nglml; Figure P~; 21.3% reduction, P= 0.006 versus control). 
In addition to colony area, treatment of the human BEC explants with 1,000 nglml of cyclosporine, 
but not tacrolimus, significantly inhibited hBEC BrdU labeling (Figure PBF~ . 
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Figure 3. A: The effect of cyclosporine and tacrolimus on the 
growth of human BECs was tested on human bile-duct tree 
explants (hBDT), as described in the Materials and Methods. On 
average, five explant cultures were included in each treatment 
group. Measurements of culture size were made every 2 days for 6 
days. Note the increase in culture size in both the control and 
tacrolimus-containing media, compared to the significant decrease 
in size of the cyclosporine-treated cultures (*, P < 0.02; **, P < 
0.006 compared to control or tacrolimus-treated cultures). B: To 
show that the diminished size of the BEC cultures was related to 
mito-inhibition, the cultures were also labeled with BrdU for either 
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o or 1L hours belore lIXatlon lor ant1-.l:Srd.U stammg. Note the 
significantly lower percentage ofBrdU+ BEC nuclei in the 
cyclosporine-treated cultures, compared to the others (*, P < 0.01 
versus BEC cultures treated with 1,000 ng/ml cyclosporine). 
Because human BECs are not always conveniently available, we also determined whether either 
cyclosporine or tacrolimus also directly influenced mBEC proliferation, in vitro, in anticipation of 
further mechanistic studies. For these experiments, mBECs were cultured in C-SFM, without the 
addition of other growth factors or other growth supplements, other than the drugs. The addition of 
cyclosporine (100 ng/ml to lO,OOO ng/ml) to mBECs caused a significant, concentration-dependent 
inhibition of [3H]-thymidine incorporation throughout a period of 48 hours (Figure 4F~ , compared to 
mBECs kept in control media or media supplemented with tacrolimus. In contrast, no significant 
growth inhibition was seen after the addition of 0.1 to 10,000 ng/ml tacrolimus to mBECs. Blood and 
bile cyclosporine concentrations generally range from 10- to 100-fold higher than tacrolimus.28-1Z 
However, even when tested in a similar concentration range, tacrolimus did not impact BEC growth 
compared to cyclosporine, which has been found in the bile of liver allograft recipients at 
concentrations ranging from 500 to >6,000 ng/ml. 33 Given that the human BECs and mBECs 
responded similarly to treatment with either tacrolimus or cyclosporine, the following mechanistic 
studies were conducted in mBECs because oftheir predictable availability . 
..... - Figure 4. Treatment of mBECs kept in C-SFM with I~D1; '::::::,'.'111 j" I' ,r·:'-'I .. l ... :;~FI~;:s~~c:~!:~~::f:~~~~~~~::t~~c~:~!~l:bCp 
. em-thymidine incorporation after 48 hours, compared to 
mBECs treated with tacrolimus (0.1 to 10,000 ng/ml). The 
'---___ ---.;.-;;;:.;.;;: .. ~KI-__ -_-__ - .... results shown are representative of at least three separate 
View larger version (17K): 
[in this window] 
[in a new window] 
experiments (*, P < 0.01; **, P < 0.001; ***, P < 0.0003). 
Effect of mBEC Treatment with Cyclosporine and Tacrolimus on TGF-j3 mRNA 
Expression and Protein Secretion 
We next determined whether treatment ofmBECs with either cyclosporine or tacrolimus caused an 
increase in mBEC TGF-B mRNA production and TGF-B protein secretion into the culture 
supernatant. Treatment ofmBECs with a growth-inhibitory concentration ofcyclosporine (5,000 
nglml), but not a supraimmunosuppressive concentration oftacrolimus, increased mBEC TGF-B 
mRNA production, as determined by a standard ribonuclease protection assay (Figure 5, A and BF~ . 
Although the increase in TGF-B mRNA is small, the half-life ofthis mRNA is increased in 
cyclosporine-treated T cells. 3.+ Treatment ofmBECs with cyc1osporine (1,000 ng/ml) also resulted in a 
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significant increase ofTGF-B protein secretion in the mBEC supernatant, compared to mBECs kept 
either in the control media alone, or media supplemented with the same concentrations of tacrolimus 
(1,000 ng/ml; Figure RCi~gFK 
"II 
1.1t 
Figure 5. A: Treatment of mBECs kept in C-SFM with 
cyclosporine (5,000 ng/ml), but not tacrolimus (1,000 ng/ml) 
caused an increase ofTGF-B mRNA production, as 
°iAl!!!--D~~~!:-1 determined by a standard ribonuclease protection assay. If the 
mBECs were growth arrested by switching to simple serum-
free medium (S-SFM) (see Materials and Methods) there was 
also an increase in TGF-B production. B: Densitometry 
_0._0 ___ " tracing and comparison to GAPDH mRNA showed that TGF-
View larg-e-r-v-e-rs-i-on-(3-8-K-)-: ..... B mRNA production is higher in the cyclosporine-treated than 
in the tacrolimus-treated cultures. The determinations were [in this window] 
[in a new window] performed 24 hours after the addition of the drugs to the 
mBEC cultures kept in C-SFM. The results shown are 
representative ofthree separate experiments. C: Treatment of 
mBECs kept in C-SFM with cyclosporine (1,000 ng/ml), but 
not tacrolimus (1,000 ng/ml) for 48 hours caused an increase 
ofTGF-B protein secretion into the culture supernatant, as 
determined by a standard enzyme-linked immunosorbent assay 
(*, P < 0.005). 
Activation ofTGF-j3 Intracellular Signaling 
We have previously shown that TGF-B inhibits human BEC growtho 35 In most epithelial cells, TGF-B 
inhibits growth by interacting with the membrane bound TGF -B receptor II, which in turn, dimerizes 
with TGF-B receptor I and initiates intracellular signaling through serine/threonine kinase activity. 
TGF-B receptor I phosphorylates serine residues on SMAD-2, which associates with SMAD-4 and the 
complex is translocated into the nucleus. TGF-B signaling also increases expression ofTGF-B receptor 
11. 36 Therefore, we next examined cyclosporine-treated mBECs for evidence ofqdc-B-~ediated 
signaling using immunoblotting for TGF-B receptor II expression and phosphorylation ofSMAD-2. 
Figure S~ shows that cyclosporine treatment ofmBEC increases TGF-B receptor II protein 
expression, compared to mBEC kept in tacrolimus-supplemented media; there is also increased 
SMAD-2 phosphorylation (Figure 6B)oo in the cyclosporine-treated, but not in the tacrolimus-treated 
mBECs . 
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Figure 6. A: Treatment of mBECs kept in C-SFM with 
cyclosporine (1,000 ng/ml) or TGF-B (10 ng/ml) for 48 hours, 
but not tacrolimus (1,000 ng/ml) results in up-regulation of the 
TGF-B receptor type II protein compared to C-SFM controls 
(left) as determined by Western blotting. Densitometry tracing 
was used to illustrate the quantitative differences (right). B: 
TGF-B signaling pathway is mediated by phosphorylation of 
the transcription factor SMAD-2. In this Western blot (left), 
total cellular protein was probed for phospho-SMAD-2, which 
was detected in the mBECs treated with cyclosporine (1,000 
ng/ml), but not with tacrolimus (1,000 ng/ml). The positive 
L....-V-ie-w-la-rg-er-v-e-rs-i-o-n-(-33-K-)-: ..... control consisted ofmBECs treated with 10 ng/ml of 
[in this window] exogenous TGF-B. Densitometry tracing was used to illustrate 
[in a new window] the quantitative differences (right). C: In this Western blot, 
BEC nuclear protein was probed for the cyclin-dependent 
kinase inhibitor protein, p21 WAF IICip 1, which is elevated 48 
hours after treatment with either TGF-B (10 ng/ml; positive 
control) or cyclosporine (1,000 ng/ml), but not in the control 
C-SFM or after treatment with tacrolimus (1,000 ng/ml). 
TGF-B inhibits epithelial cell proliferation via an increase in p21 WAFIICipl, which is a universal 
inhibitor of cyclin-CDK activity. 37-40 Consistent with these studies, the cyclosporine-treated mBECs 
showed increased nuclear p21 WAFIICipl protein expression compared to tacrolimus-treated mBECs 
(Figure SCF~ . 
The Effect of Cyclosporine on mBEC Proliferation in Vitro Can Be Reversed by 
Neutralizing Anti-TGF-,P Antibody 
In an effort to determine whether the decreased proliferation seen in cyclosporine-treated mBEC 
cultures is attributable to TGF-B-mediated mito-inhibition, mBECs were simultaneously treated with a 
combination of 1,000 ng/ml cyclosporine and increasing concentrations of neutralizing ~ti-TGF-B 
antibody for 48 hours (Figure TF~ . The addition of anti-TGF-B monoclonal antibody (10 to 100 
/lg/ml) resulted in a significant increase in [3H]-thymidine incorporation compared to mBECs treated 
with the combination of cyclosporine and control IgG at the same concentrations. These results 
confinn that autocrine/paracrine TGF-B signaling is responsible for the cyclosporine-mediated 
inhibition ofBEC growth . 
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Figure 7. The simultaneous addition of 1,000 ng/ml 
cyclosporine and neutralizing anti-TGF-B antibodies to 
rnBECs in C-SFM caused a concentration-dependent increase 
in eH]-thymidine incorporation after 48 hours, compared to 
rnBECs treated with 1,000 nglml cyclosporine and control 
nonimmune immunoglobulin. This result further confirms that 
L-____ .....:..==;:.;. •• .;...I _ ...... inhibition ofBEC growth, in vitro, is mediated via TGF-B. 
View larger version (IlK): The results shown are representative of two separate 
[in this window] experiments (*, P < 0.002; **, P < 0.0003). 
[in a new window] 
~ Discussion 
This study shows that the disappearance ofBECs in CR is preceded by a 
period of mito-inhibition and cellular senescence, marked by characteristic 
cytological alterations and up-regulation of nuclear p21 WAFlICipl. Because 
recognition ofthe BEC cytological alterations in liver allograft biopsies is 
..... TOI) 
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..... Materials and Methods 
..... Results 
• Discussion 
.... odere~ces 
somewhat subjective but essential for establishing the diagnosis of early CR 1.'========:dJ 
and distinguishing it from other causes of late liver allograft dysfunction, BEC p21 WAF l/Cip 1 
expression can be used as an ancillary test to help establish the diagnosis. Caution is urged however, 
because BEC p21 W AFlICip 1 expression can also be increased in obstructive cholangiopathy, which can 
also cause ductopenia and be confused histologically with early CR.l Thus, it is not unreasonable to 
suggest that up-regulation of p21 W AFI/Cip 1 might be a common mechanism that precedes ductopenia 
in other liver diseases. 
Both direct immunological damage and ischemia contribute to bile duct injury during early CR, 41,42 
but molecular mechanism(s) responsible for disappearance of the BECs have not been clarified. The 
:final common pathway seems to be BEC apoptosis, but the data are somewhat conflicting. Nawaz and 
colleagues±.1 detected apoptotic BECs in acute rejection, but in CR, Afford and colleagues44 were 
unable to detect significant BEC apoptotic activity using the terminal dUTP nick-end labeling assay. 
Given that BEC account for only a small fraction of the cells in the liver, and apoptosis of any 
individual cell is detectable for only a few hours, BEC apoptosis may be difficult to catalog in CR. In 
addition, p21 WAFlICipl can bind to procaspase 3 precursor45 and block its processing and activation. 
Thus, increased p21 WAF lICip 1 expression might actually protect BECs against Fas-Fas-L-induced 
apoptosis, which is the mode ofBEC injury in a graft-versus-host diseas&Q that CR closely resembles. 
It is likely that up-regulation ofBEC p21 WAFlICipl occurs as a result of the prolonged bile duct injury 
in early CR, but given some of its functions, the increased expression of p21 W AFlICip 1 has the 
potential to importantly contribute to the pathophysiology. First, p21 WAFIICipl can potentially protect 
BECs from apoptosis. However, it also seems to exert its known mito-inlnbitory function in early CR 
because the BECs do not proliferate in response to injuryK1I~l Secondly, forced overexpression of 
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p21 WAFI/Cipl protein using an inducible promoter, causes cellular senescence,l-+ including growth 
arrest and cytological changes such as those seen in the BECs in early CR. It also causes up-regulation 
of genes that encode for extracellular matrix components, such as fibronectin-l, plasminogen activator 
inhibitor-I, tissue-type plasminogen activator, Mac-2-binding protein, and extracellular matrix 
receptors (integrin B3), which might explain thickening of the basement membrane in CR. Lastly, 
clinical and histopathological recovery from CR is associated with decreased BEC nuclear 
p21 WAF IICip 1 expression. 
The gene encoding p21 WAFliCipl is regulated by at least three classes of signals that result in growth 
arrest: 1) the tumor suppressor protein p53, which is activated by DNA damage; 2) extracellular 
growth factors, acting in a p53-independent manner, such as tumor necrosis factor-cr (TNF-cr), TGF-B, 
activin, phorbol esters, retinoic acid, and others; and 3) factors that induce cellular differentiation of 
many cell types ... 1,7 In early CR, cytokines, growth factors, or other immunological effector 
mechanisms/molecules produced as a result of (or in response to) immunological injury (eg, TNF -cr, 
TGF-B) are most likely to be the underlying cause for increased expression ofBEC p21 WAFIICipl. 
This contention is based on the fact that the number and severity of acute rejection episodes are the 
most significant risk factors for the development of CR. :;-1 In addition, Demirci and colleagues48 
showed increased TGF-B protein in the portal tracts and perivenular regions of liver allografts with 
CoK±~ 
When CR does occur, cyclosporine-treated recipients develop more bile duct loss and fibrosis than 
tacrolimus-treated recipients who develop CR.:;'() In cyclosporine-treated patients, the median 
percentage of bile duct loss was 100% in allografts that failed because ofCR; only one of 13 grafts 
had bile duct loss in <50% of the portal tracts.:; In contrast, the median percentage of bile duct loss in 
allografts that failed from CR in tacrolimus-treated patients was only 43%. § Severe (bridging) 
perivenular fibrosis was also seen in most of the failed allografts from cyclosporine patientsI~ but was 
uncommon in the graft from the tacrolimus-treated cohort. § In addition, several clinical trials have 
shown that if cyclosporine-treated recipients with early CR are converted to tacrolimus, the clinical, 
biochemical, and histopathological manifestations ofCR can be reversed1,:;,Q,19-21 and bile duct loss, 
which is a late feature of CR, 1 can be prevented. Rare cases of spontaneous reversal of CR have also 
-, ~ 
been reported. -,,) 
The increased p21 WAFliCipi in early CR is immunologically mediated and clearly not drug-specific. 
However, the ability ofcyclosporine, but not tacrolimus, to stimulate BEC production ofTGF-Bl, in 
vitro, along with the less potent immunosuppressive properties of cyclosporine, might explain the 
lower incidence ofCR under tacrolimus therapy and it's relative duct-sparing properties. Cyclosporine 
(but not tacrolimus), also inhibits the growth of mink lung epithelial cellsI~4 human airway epithelial 
cells,2J and murine proximal tubular ceUs±2 by activating the TGF-B promoter50,51 and stimulating 
TGF-B production. Cyclosporine-induced BEC TGF-B production up-regulates TGF-B receptor II 
receptor expression, phosphorylation of the transcription factor SMAD-2 and nuclear translocation of 
p21 WAFIICipl. Once immunological damage to the bile ducts has occurred, our in vitro studies 
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provide mechanistic support for the clinical conclusion that tacrolimus is more effective in treating and 
preventing ductopenic rejection than cyclosporineK19IO1IRl-~1 Both cyclosporine and tacrolimus are 
metabo lized by the liver and excreted in the bile, where both residual native drug (usually 1 % or less) 
and metabolites (some of which have immunosuppressive properties) can be detected at concentrations 
higher than in the blood or serumK4~-gl Thus, any potential direct effect of these drugs on BEC 
physiology could be magnified by exposure both via the blood stream and the bile. 
It is important to note that the differential effects of the immunosuppressive drugs on BEC growth 
were detected in primary BEC cultures, and the culture conditions are not equivalent to normal 
conditions in vivo. The culture conditions are stressful and the basal medium contains an adenylate 
cyclase stimulator, which increases BEC interleukin-6 production}.2 In contrast, the vast majority of 
normal BECs in vivo are in Go phase of the cell cycle)S Thus, the in vitro conditions used in this 
study most accurately simulate a stressful BEC microenvironment,25 such as that seen in early CR. 
This is consistent with the observation that neither cyclosporine nor tacrolimus alone induces either 
BEC cytological alterations or BEC up-regulation ofp21 WAFlICipl in liver allograft recipients in the 
absence of early CR or other causes of ductal injury. Thus, in vivo, the difference between the two 
drugs becomes apparent only after BEC injury. This situation is similar to the ability oftacrolimus, but 
not cyclosporine, to promote the growth and repair of damaged peripheral nerves, 59,('jQ via a 
calcineurin-independent pathway, involving FK binding protein (FKBP)-52, steroid receptors, and hsp-
90. Interestingly, both steroid receptors and hsp-90 are expressed in BECs, and up-regulated after 
BEC injury. 61 The profile ofBEC FKBP expression has not been investigated. 
Lastly, this study validates the notion that replicative senescence of epithelial cells can contribute to 
the pathobiology of chronic rejection. ~~ Thus, even though CR of liver allografts is relatively 
uncommon, further study might provide useful information about the potential role of stimulation of 
epithelial growth on CR. (i 
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